Cardiac complications observed in elderly patients following 2′‐deoxycoformycin therapy
- 1 November 1991
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 38 (3), 245-247
- https://doi.org/10.1002/ajh.2830380320
Abstract
Deoxycoformycin (dCF) is an investigational nucleoside with significant activity in hairy cell leukemia, cutaneous T-cell lymphoma, and chronic lymphocytic leukemia. During a 4-year period, 11 patients have experienced cardiac events as a complication of dCF therapy under NCI sponsorship. The cases are presented and recommendations for the administration of dCF to patients with pre-existing heart disease are made.Keywords
This publication has 6 references indexed in Scilit:
- Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.Journal of Clinical Oncology, 1989
- 2′-Deoxycoformycin (Pentostatin) for Lymphoid MalignanciesAnnals of Internal Medicine, 1988
- Clinical consequences of 2′-deoxycoformycin treatment in patients with refractory adult T-cell leukaemiaLeukemia Research, 1986
- Treatment of lymphoid malignancies with 2'-deoxycoformycin A pilot studyAmerican Journal of Clinical Oncology, 1982
- Acute respiratory failure due to 2′ deoxycoformycinIntensive Care Medicine, 1982